youtube_live
Q3 2026 earnings ā¢ in 5 days
See detailschevron_right
GENB:NASDAQ
Generate Biomedicines Inc
$13.06
arrow_upward
+3.90%(+0.49) 1D
Nov 6, 4:00:01āÆPM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GENB...
Open
$12.90
High
$13.17
Low
$12.47
Mkt. cap
1.68B
Avg. vol.
1.04M
Volume
632.20K
52-wk high
$22.67
52-wk low
$11.00
No. of employees
312
Open
$12.90
High
$13.17
Low
$12.47
Mkt. cap
1.68B
Avg. vol.
1.04M
Volume
632.20K
52-wk high
$22.67
52-wk low
$11.00
No. of employees
312
News stories
From web sources and news partners
BigGo Finance
·
10 hours ago
Global AI and Semiconductor Stocks Plunge; S&P 500 Tumbles 4.4% in a Single Day as Markets Watch Whether Three Central Banks Will Raise Rates in December
The Motley Fool
·
21 hours ago
This Dividend King Yielding 2X the S&P 500 Looks Like a Buy in November.
Briefs Finance
·
20 hours ago
Inflation Mentions Hit S&P 500 Earnings Calls Peak
Profile
Generate:Biomedicines is a biotechnology company founded in 2018 and headquartered in Somerville, Massachusetts. It specializes in using machine learning to design and optimize proteins for therapeutic applications, with a focus on immunology, oncology, and infectious diseases. Wikipedia
About Generate Biomedicines Inc
CEO-
Employees312
Founded2018
HeadquartersSomerville, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitegeneratebiomedicines.com
Analyst ratings
Based on 3 analysts giving stock ratings to GENB in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for GENB in the last 3 months.
Highest
Current $13.06
$30.00 (+129.71%)
Average
$26.00 (+99.08%)
Lowest
$22.00 (+68.45%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Mitchell Kapoor H.C. Wainwright | Buy | Maintained | $30.00 | +129.7% | 11/02/2026 |
Edward Tenthoff Piper Sandler | Buy | Reiterated | $26.00 | +99.1% | 10/14/2026 |
Sean Laaman Morgan Stanley | Buy | Reiterated | $22.00 | +68.5% | 08/17/2026 |
Seamus Fernandez Guggenheim | Buy | Reiterated | $30.00 | +129.7% | 06/24/2026 |
Salveen Richter Goldman Sachs | Buy | Maintained | $26.00 | +99.1% | 04/09/2026 |
Eric Schmidt FCA Cantor Fitzgerald | Buy | Initiated | - | - | 03/24/2026 |
Next call in 5 days
Fri, Nov 13, 4:30āÆPM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.55
Revenue / Est. (USD)
- / 7.75M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 8.82M | 10.13M | 7.22M | 6.31M |
Cost of goods sold | 46.82M | 59.74M | 57.81M | 64.33M |
Cost of revenue | 46.82M | 59.74M | 57.81M | 64.33M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 10.15M | 10.54M | 13.52M | 13.60M |
Operating expense | 10.15M | 10.54M | 13.52M | 13.60M |
Total operating expenses | 56.97M | 70.28M | 71.34M | 77.93M |
Operating income | -48.15M | -60.15M | -64.11M | -71.61M |
Other non operating income | - | - | -363.00K | - |
EBT including unusual items | -44.26M | -56.70M | -61.69M | -67.20M |
EBT excluding unusual items | -44.26M | -56.70M | -61.69M | -67.20M |
Income tax expense | 56.00K | 44.00K | 28.00K | 53.00K |
Effective tax rate | -0.13% | -0.08% | -0.05% | -0.08% |
Other operating expenses | - | - | - | - |
Net income | -41.68M | -52.43M | -61.45M | -67.26M |
Net profit margin | -472.73% | -517.56% | -850.58% | -1,065.17% |
Earnings per share | - | - | -1.07 | -0.52 |
Interest and investment income | 4.28M | 3.79M | 2.91M | 4.63M |
Interest expense | -368.00K | -307.00K | -182.00K | -155.00K |
Net interest expenses | 3.91M | 3.48M | 2.73M | 4.47M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -46.84M | -54.73M | -63.04M | -66.19M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events